Selective Androgen Receptor Modulators (SARMs) represent one of the most pharmacologically interesting classes of research compounds in endocrinology, with combined monthly search volume exceeding 50,000 queries. Unlike anabolic steroids — which activate androgen receptors non-selectively throughout all tissues — SARMs were designed to achieve tissue selectivity: anabolic effects in muscle and bone with reduced activity in androgenic tissues (prostate, skin, hair follicles). This guide covers the pharmacology, selectivity profiles, and research applications of the most widely studied SARMs.
The Science of Selectivity: How SARMs Work
All SARMs share a common mechanism: binding to the androgen receptor (AR). The “selective” prefix refers to differential tissue outcomes, which arise from three mechanisms:
- Differential coactivator recruitment: When a SARM binds the AR in different tissues, it induces slightly different receptor conformations. These conformations recruit different coactivator proteins — some promoting transcription (muscle anabolic genes), others not (prostate androgenic genes).
- Tissue-specific coactivator expression: Different tissues express different complements of AR coactivators and corepressors. The same AR-SARM complex produces different gene expression outcomes depending on which coactivators are available in a given cell type.
- Metabolic stability: Unlike testosterone, SARMs are not substrates for 5α-reductase (the enzyme that converts testosterone to the more potent DHT in androgenic tissues), nor for aromatase (which converts testosterone to estradiol). This eliminates two major pathways for androgenic side effects.
RAD-140 (Testolone) — Highest Anabolic Selectivity
RAD-140 (Testolone) consistently produces the highest anabolic-to-androgenic selectivity ratios in published research — approximately 90:1 in animal models, compared to testosterone’s 1:1 baseline. Developed by Radius Health, RAD-140 entered Phase I/II clinical trials for breast cancer and Alzheimer’s disease, providing a clinical-grade safety database unusual for research SARMs.
Key RAD-140 research findings:
- Muscle anabolism: RAD-140 produced significant lean mass increases in preclinical primate models at doses producing minimal prostate stimulation — the core selectivity demonstration
- Neuroprotection: An unexpected finding from Alzheimer’s research: RAD-140 activates neuroprotective AR signaling in hippocampal neurons, reducing amyloid-beta toxicity in cell culture models and protecting against kainate-induced neurotoxicity in animal studies
- Breast cancer: RAD-140 inhibits AR/ER cross-talk in ER+/AR+ breast cancer cell lines, driving anti-proliferative effects — the rationale for its cancer research program
- No 5α-reduction: RAD-140 is not converted to a more potent form in androgenic tissues, a key pharmacological advantage over testosterone in anabolic research
LGD-4033 (Ligandrol) — Most Clinically Validated Anabolic SARM
LGD-4033 (Ligandrol, VK5211) is the most clinically validated anabolic SARM in existence. Developed by Ligand Pharmaceuticals (now Viking Therapeutics), LGD-4033 completed Phase II trials for hip fracture rehabilitation and produced statistically significant lean muscle mass increases (1.21 kg vs placebo) at just 1mg/day over 21 days — with no change in PSA, hematocrit, or LH/FSH beyond mild temporary suppression.
LGD-4033 research applications:
- Muscle wasting models: Sarcopenia, cachexia, and disuse atrophy models in aged animals — the compound’s most-published research area
- Bone density research: Phase II data shows improved bone mineral density and functional recovery in hip fracture patients, making LGD-4033 relevant to osteoporosis research
- Selectivity profiling: LGD-4033’s clean Phase I safety data (no hepatotoxicity, minimal androgenic signals) makes it the reference SARM for tissue-selectivity mechanism studies
MK-677 (Ibutamoren) — The Non-Peptide GH Secretagogue
MK-677 (Ibutamoren) is technically not a SARM — it is a non-peptide ghrelin receptor (GHS-R1a) agonist and growth hormone secretagogue. It is categorized alongside SARMs in research communities because it is orally bioavailable, studied for similar anabolic/anti-catabolic purposes, and commonly combined with SARMs in research protocols. MK-677’s mechanism is distinct: it stimulates endogenous GH and IGF-1 secretion rather than activating androgen receptors.
MK-677 offers unique research advantages:
- Oral bioavailability: Unlike peptide GH secretagogues (CJC-1295, Ipamorelin), MK-677 is orally active — enabling studies where injection administration is impractical
- 24-hour GH elevation: A single oral dose maintains elevated GH and IGF-1 for 24 hours, compared to the short pulses produced by injectable GHRPs
- Phase III clinical data: MK-677 completed Phase III trials for growth hormone deficiency and Alzheimer’s disease, producing the most comprehensive clinical safety database of any GH secretagogue
- Appetite stimulation: GHS-R1a activation increases appetite — a useful effect in cachexia research models but a confounder to control in pure anabolic studies
Ostarine (MK-2866) — The Reference SARM for Muscle Preservation
Ostarine (Enobosarm, MK-2866) is the reference SARM in published research — the most extensively published non-steroidal AR agonist in clinical literature. GTx/Merck ran the largest SARM clinical program in history (POWER1 and POWER2 trials, 600+ patients) studying Ostarine for cancer-related muscle wasting. While the trials missed statistical significance on the primary endpoint, the data established the most detailed human AR selectivity profile available for any SARM.
As a research compound, Ostarine is ideal for:
- Establishing baseline SARM activity in new models (well-characterized behavior)
- Muscle preservation studies in catabolic states (cancer, immobilization, aging)
- AR pharmacology mechanistic research (extensive structure-activity data published)
- Comparing SARM selectivity profiles head-to-head (Ostarine as internal reference compound)
Cardarine (GW501516) — PPARδ Agonist and Endurance Research Tool
Cardarine (GW501516) is not a SARM and does not bind the androgen receptor — it is a PPARδ (Peroxisome Proliferator-Activated Receptor delta) agonist. It appears in SARM research catalogs because its studied effects (fat oxidation, endurance enhancement, fiber type conversion) complement SARM anabolic research. The Evans lab landmark study demonstrated GW501516 increased endurance in sedentary mice by 77% — among the most striking single-compound endurance findings in the literature.
Cardarine research context:
- PPARδ pathway studies: Cardarine is the standard PPARδ agonist used in metabolic and exercise biology research
- Fiber type conversion: Activates fast-to-slow twitch fiber type conversion (increasing Type I oxidative fibers) through PGC-1α upregulation
- Lipid metabolism: Reduces LDL, increases HDL, and upregulates genes for fatty acid β-oxidation in muscle tissue
- Important research note: GW501516 was discontinued in clinical development due to accelerated carcinogenesis in long-term rat studies. This finding is itself a research subject — studying the dose/duration relationship of PPARδ agonism and proliferative risk is an active area of investigation
SARM Comparison Reference Table
| Compound | Receptor Target | Selectivity Ratio | Clinical Stage | Primary Research Use |
|---|---|---|---|---|
| RAD-140 | AR | ~90:1 | Phase I/II | Anabolic selectivity, neuroprotection |
| LGD-4033 | AR | ~20:1 | Phase II complete | Muscle wasting, bone density |
| Ostarine | AR | ~3:1 | Phase III (discontinued) | Reference SARM, cancer cachexia |
| MK-677 | GHS-R1a | N/A (non-AR) | Phase III complete | Oral GH secretion, GHD |
| Cardarine | PPARδ | N/A (non-AR) | Discontinued Phase II | Endurance, lipid metabolism |
| Andarine (S4) | AR | ~10:1 | Preclinical | Bone density, early SARM pharmacology |
| YK-11 | AR + Myostatin | N/A (dual) | Preclinical only | Myostatin inhibition, anabolism |
SARMs Research Combinations
SARM combination studies explore additive or synergistic effects across different receptor systems. Common research designs:
- AR SARM + MK-677: Combines direct AR anabolism (RAD-140 or LGD-4033) with GH/IGF-1 elevation (MK-677) — a dual-pathway anabolic protocol commonly used in muscle preservation research
- SARM + Cardarine: Pairs anabolic AR agonism with PPARδ metabolic enhancement — useful for studying body composition (muscle gain + fat loss) in animal models without caloric restriction
- Ostarine + Enclomiphene: Studies hormonal axis recovery — Ostarine’s suppression of LH/FSH modeled against Enclomiphene’s SERM-mediated LH restoration
All SARMs Available at Rainbow Peptide
Rainbow Peptide carries the complete SARMs research catalog: RAD-140, LGD-4033, Ostarine (MK-2866), MK-677 (Ibutamoren), Andarine (S4), Cardarine (GW501516), SR9009 (Stenabolic), YK-11, and Enclomiphene — all verified at >98% HPLC purity with third-party COA documentation.
For Research Use Only (RUO). All SARMs sold by Rainbow Peptide are for in vitro and laboratory research purposes only. Not for human consumption. Not for use in clinical trials without appropriate regulatory approvals. Not intended to diagnose, treat, cure, or prevent any disease.